Drug news
Vibativ is EU approved for nosocomial pneumonia caused by MNSA
Astellas and Theravance have received marketing authorisation from the European Commission for Vibativ (telavancin hydrochloride) for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Its labelling will include its use in the treatment of adults with nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. In the US and Canada, the drug was approved in 2009 for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of certain Gram-positive microorganisms, including Staphylococcus aureus ,including methicillin-susceptible and-resistant isolates but is not approved in these territories for the pneumonia indication. Vibativ is not yet available in Europe for use with skin such infections as are approved in the USA.